Beyond low-density lipoprotein cholesterol. A perspective on low high-density lipoprotein disorders and Lp(a) lipoprotein excess.
Evidence supports the involvement of 2 common dyslipidemias---low high-density lipoprotein disorders and Lp(a) lipoprotein excess--in coronary heart disease. Until clinical trials determine whether specific therapeutic interventions can prevent the occurrence and recurrence of coronary heart disease in patients with these dyslipidemias, the implementation of cholesterol-lowering guidelines can provide a reasonable way to manage low high-density lipoprotein disorders and to identify specific categories of patients who may be at particularly high risk for premature coronary heart disease. Empiric treatment guidelines are suggested for low high-density lipoprotein disorders and Lp(a) lipoprotein excess in order to foster further discussion and validation by clinical trial data.
Rosenson
R S
RS
Preventive Cardiology Center, Rush-Presbyterian-St Luke's Medical Center, Chicago, Ill., USA.
D008076:Cholesterol, HDL / Q000097:blood*; D008078:Cholesterol, LDL / Q000097:blood*; D003327:Coronary Disease / Q000097:blood / Q000209:etiology; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000150:complications; D017270:Lipoprotein(a) / Q000097:blood*
D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D017270:Lipoprotein(a)